- Hemostemix (HEM) has signed a global master services agreement with My Next Health
- The company has obtained a US$150,000 subscription from My Next Health
- MNH has created the world’s first functional genomic AI-based tool that delivers precision medical care
- Hemostemix will incorporate MNH’s functional genomic assays to complete an assay report
- Next Health is a leading AI-functional-medicine-based genomic medical analysis company
- Hemostemix Inc. (HEM) is up 7.69 per cent, trading at C$0.14 at 1:23 pm EST
Hemostemix Inc. (HEM) has signed a global master services agreement with My Next Health.
Hemostemix has also obtained a US$150,000 subscription from My Next Health at C$0.25 per unit.
My Next Health Inc. is a leading patient-based AI-functional genomic medical analysis company.
MNH is improving human health and accelerating the world’s transition to precision medicine.
From completing more than 10,000 in-person patient assessments and from its comparison of that database to 60 million patient records, MNH has created the world’s first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual’s health recommendations and clinical trial outcomes.
MNH algorithms significantly impact clinical trial subject selection.
Hemostemix will incorporate MNH’s functional genomic assays to complete an assay report by an individual.
Such analyses will enable Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double-blind placebo-controlled clinical trial.
“We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools, to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine,” stated Dr. Richard Heinzl, CEO of MNH.
“MNH’s tools and analyses enable Hemostemix to explain when, how and why ACP works. These innovations improve the underpinnings of our therapeutics markets, and significantly de-risks our clinical trials going forward,” stated Thomas Smeenk, President & CEO of Hemostemix.
MNH is focused on improving human health and accelerating the world’s transition to precision medicine.
Hemostemix Inc. (HEM) is up 7.69 per cent, trading at C$0.14 at 1:23 pm EST.
